STERIS PLC

STE

Equity

ISIN IE00BFY8C754 / Valor 47027903

New York Stock Exchange, Inc (2024-09-17)

USD 241.68-0.84%

STERIS PLC
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

STERIS PLC, originally founded as Innovative Medical Technologies in Ohio in 1985 and renamed in 1987, has grown into a leading global provider in infection prevention and procedural products and services. With a history enriched by acquisitions, such as the American Sterilizer Company, STERIS now boasts a workforce of approximately 16,000 associates and operates in over 100 countries. The company's portfolio spans a broad range of innovative capital equipment, including sterilizers, washers, surgical tables, and lights, alongside equipment management systems and connectivity solutions aimed at integrating operating rooms. Additionally, STERIS offers a variety of consumable products, from detergents to gastrointestinal endoscopy accessories and dental instruments. Its service offerings are comprehensive, covering equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair solutions, laboratory services, and off-site reprocessing. Central to STERIS's mission is its commitment to supporting patient care by focusing on infection prevention, thereby aiding healthcare, life sciences, and dental sectors in creating healthier and safer environments.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

STERIS PLC reported a 10% increase in total revenue for the fourth quarter of fiscal 2024, reaching $1.5 billion compared to $1.4 billion in the same quarter of fiscal 2023. For the full fiscal year 2024, total revenue increased by 12% to $5.5 billion, up from $5.0 billion in fiscal 2023.

Earnings Per Share

For the fourth quarter of fiscal 2024, STERIS PLC's U.S. GAAP net loss was $1.4 million or ($0.01) per diluted share, compared to net income of $187.2 million or $1.88 per diluted share in the fourth quarter of fiscal 2023. Adjusted earnings per diluted share for the fourth quarter increased to $2.58 from $2.30 in the same period last year.

Segment Performance

In the fourth quarter of fiscal 2024, STERIS PLC's Healthcare segment revenue grew by 14% to $1,007.9 million, driven by a 19% increase in capital equipment revenue, 14% growth in consumable revenue, and 9% growth in service revenue. The Applied Sterilization Technologies (AST) segment saw a 5% increase in revenue to $250.9 million.

Cash Flow

STERIS PLC reported net cash provided by operations of $973.3 million for fiscal 2024, compared to $756.9 million in fiscal 2023. Free cash flow for fiscal 2024 was $620.3 million, up from $409.6 million in the prior year, driven by higher cash generation from operations and reduced working capital requirements.

Fiscal 2025 Outlook

For fiscal 2025, STERIS PLC expects revenue from continuing operations to increase by 6.5-7.5%. Adjusted earnings per diluted share from continuing operations are anticipated to be in the range of $9.05 to $9.25, compared to $8.20 in fiscal 2024. The company also expects capital expenditures to be approximately $360 million and free cash flow to be around $700 million.

Summarized from source with an LLMView Source

Key figures

5.31%1Y

12.4%3Y

66.1%5Y

Performance

22.0%1Y

27.7%3Y

29.1%5Y

Volatility